Immune competence after alemtuzumab treatment of multiple sclerosis

Neurology

Volumn 81, Issue 10, 2013, Pages 872-876

  McCarthy, Claire L ^a   Tuohy, Orla ^a   Compston, D Alastair S ^a   Kumararatne, Dinakantha S ^b   Coles, Alasdair J ^a   Jones, Joanne L ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; DIPHTHERIA ANTIBODY; DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; T LYMPHOCYTE ANTIGEN; TETANUS ANTIBODY; TETANUS TOXOID; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CASE CONTROL STUDY; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DIPHTHERIA; DISEASE DURATION; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENCE; IMMUNOLOGICAL MEMORY; INFLUENZA B; MALE; MENINGOCOCCOSIS; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MUMPS; PILOT STUDY; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; RUBELLA; SEROCONVERSION; TETANUS; TREATMENT RESPONSE; VACCINATION; VARICELLA ZOSTER VIRUS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOCOMPETENCE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PILOT PROJECTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884643373     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a35215     Document Type: Article

References (10)

1. Coles AJ. Alemtuzumab therapy for multiple sclerosis. Neurotherapeutics 2013;10:29-33.
2. Borrow R, Southern J, Andrews N, et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A/C polysaccharide vaccine and vaccine-naive controls. Vaccine 2001;19:3043-3050.
3. Dentinger CM, Hennessy TW, Bulkow LR, et al. Immunogenicity and reactogenicity to Haemophilus influenzae type B (Hib) conjugate vaccine among rural Alaska adults. Hum Vaccin 2006;2:24-28.
4. Richmond P, Goldblatt D, Fusco PC, et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 1999;18:641-646.
5. Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000;181:761-764.
6. Novartis Vaccines and Diagnostics S.r.l. Menjugate Summary of Product Characteristics. Available at: http://www.medicines. org.uk/emc/medicine/16597. Accessed April 5, 2010.
7. Laroche P, Barrand M, Wood SC, et al. The immunogenicity and safety of a new combined diphtheria, tetanus and poliomyelitis booster vaccine (Td-eIPV). Infection 1999;27:49-56.
8. Mair S, Fiquet A, Meghlaoui G, Thomas S, Ledesma E. Immunogenicity and safety of PNEUMOVAX II manufactured by a new process in older adults. Hum Vaccin 2009;5:608-613.
9. Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005;94:S1-S63.
10. Makela O, Mattila P, Rautonen N, Seppala I, Eskola J, Kayhty H. Isotype concentrations of human antibodies to Haemophilus influenzae type b polysaccharide (Hib) in young adults immunized with the polysaccharide as such or conjugated to a protein (diphtheria toxoid). J Immunol 1987;139:1999-2004.